Literature DB >> 24146022

Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.

Vivek Jain1, Dathan M Byonanebye, Teri Liegler, Dalsone Kwarisiima, Gabriel Chamie, Jane Kabami, Maya L Petersen, Laura B Balzer, Tamara D Clark, Douglas Black, Harsha Thirumurthy, Elvin H Geng, Edwin D Charlebois, Gideon Amanyire, Moses R Kamya, Diane V Havlir.   

Abstract

OBJECTIVE: In a rural Ugandan community scaling up antiretroviral therapy (ART), we sought to determine if population-based HIV RNA levels [population viral load (VL)] decreased from 2011 to 2012.
DESIGN: Serial cross-sectional analyses (May 2011 and May 2012) of a defined study community of 6300 persons in a district with HIV prevalence of 8%.
METHODS: We measured HIV-1 RNA (VL) levels on all individuals testing positive for HIV during a 5-day high-throughput multidisease community health campaign in May 2012 that recruited two-thirds of the population. We aggregated individual-level VL results into population VL metrics including the proportion of individuals with an undetectable VL and compared these VL metrics to those we previously reported for this geographic region in 2011.
RESULTS: In 2012, 223 of 2179 adults were HIV-seropositive adults (10%). Overall, among 208 of 223 HIV-seropositive adults in whom VL was tested, 53% had an undetectable VL [95% confidence interval (CI): 46 to 60], up from 37% (95% CI: 30 to 45; P = 0.02) in 2011. Seven (3%) individuals had a VL of >100,000 copies/mL in 2012, down from 21 (13%) in 2011 (P = 0.0007). Mean log (VL) (geometric mean) was 3.18 log (95% CI: 3.06 to 3.29 log) in 2012, down from 3.62 log (95% CI: 3.46 to 3.78 log) in 2011 (P < 0.0001). Similar reductions in population VL were seen among men and women.
CONCLUSIONS: Reductions in population VL metrics and a substantial increase in the proportion of persons with an undetectable VL were observed in a rural Ugandan community from 2011 to 2012. These findings from a resource-limited setting experiencing rapid ART scale-up may reflect a population-level effectiveness of expanding ART access.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24146022      PMCID: PMC4172444          DOI: 10.1097/QAI.0000000000000021

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  Use of the community viral load as a population-based biomarker of HIV burden.

Authors:  Amanda D Castel; Montina Befus; Sarah Willis; Angelique Griffin; Tiffany West; Shannon Hader; Alan E Greenberg
Journal:  AIDS       Date:  2012-01-28       Impact factor: 4.177

2.  High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.

Authors:  Frank Tanser; Till Bärnighausen; Erofili Grapsa; Jaffer Zaidi; Marie-Louise Newell
Journal:  Science       Date:  2013-02-22       Impact factor: 47.728

3.  Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe.

Authors:  Sekesai Mtapuri-Zinyowera; Memory Chideme; Douglas Mangwanya; Owen Mugurungi; Stephano Gudukeya; Karin Hatzold; Alexio Mangwiro; Gaurav Bhattacharya; Jonathan Lehe; Trevor Peter
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

4.  Community viral load as a measure for assessment of HIV treatment as prevention.

Authors:  William C Miller; Kimberly A Powers; M Kumi Smith; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2013-03-25       Impact factor: 25.071

5.  Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.

Authors:  Vivek Jain; Teri Liegler; Jane Kabami; Gabriel Chamie; Tamara D Clark; Douglas Black; Elvin H Geng; Dalsone Kwarisiima; Joseph K Wong; Mohamed Abdel-Mohsen; Nitin Sonawane; Francesca T Aweeka; Harsha Thirumurthy; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Diane V Havlir
Journal:  Clin Infect Dis       Date:  2012-12-12       Impact factor: 9.079

6.  Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.

Authors:  Katharina Kranzer; Jennifer Zeinecker; Philip Ginsberg; Catherine Orrell; Nosindiso N Kalawe; Stephen D Lawn; Linda-Gail Bekker; Robin Wood
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

Review 7.  Antiretroviral therapy in prevention of HIV and TB: update on current research efforts.

Authors:  Reuben Granich; Somya Gupta; Amitabh B Suthar; Caoimhe Smyth; David Hoos; Marco Vitoria; Mariangela Simao; Catherine Hankins; Bernard Schwartlander; Renee Ridzon; Brigitte Bazin; Brian Williams; Ying-Ru Lo; Craig McClure; Julio Montaner; Gottfried Hirnschall
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

Review 8.  Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox
Journal:  PLoS Med       Date:  2011-07-19       Impact factor: 11.069

9.  Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda.

Authors:  Gabriel Chamie; Dalsone Kwarisiima; Tamara D Clark; Jane Kabami; Vivek Jain; Elvin Geng; Laura B Balzer; Maya L Petersen; Harsha Thirumurthy; Edwin D Charlebois; Moses R Kamya; Diane V Havlir
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

10.  Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda.

Authors:  Gabriel Chamie; Dalsone Kwarisiima; Tamara D Clark; Jane Kabami; Vivek Jain; Elvin Geng; Maya L Petersen; Harsha Thirumurthy; Moses R Kamya; Diane V Havlir; Edwin D Charlebois
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more
  7 in total

1.  Longitudinal Trends in the Prevalence of Detectable HIV Viremia: Population-Based Evidence From Rural KwaZulu-Natal, South Africa.

Authors:  Alain Vandormael; Till Bärnighausen; Joshua Herbeck; Andrew Tomita; Andrew Phillips; Deenan Pillay; Tulio de Oliveira; Frank Tanser
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

2.  Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.

Authors:  Vivek Jain; Dathan M Byonanebye; Gideon Amanyire; Dalsone Kwarisiima; Doug Black; Jane Kabami; Gabriel Chamie; Tamara D Clark; James F Rooney; Edwin D Charlebois; Moses R Kamya; Diane V Havlir
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

3.  Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.

Authors:  Jennifer A Smith; Monisha Sharma; Carol Levin; Jared M Baeten; Heidi van Rooyen; Connie Celum; Timothy B Hallett; Ruanne V Barnabas
Journal:  Lancet HIV       Date:  2015-04       Impact factor: 12.767

4.  Global HIV epidemiology: A guide for strategies in prevention and care.

Authors:  Sten H Vermund
Journal:  Curr HIV/AIDS Rep       Date:  2014-06       Impact factor: 5.071

5.  Estimating the impact of universal antiretroviral therapy for HIV serodiscordant couples through home HIV testing: insights from mathematical models.

Authors:  Sarah T Roberts; Aditya S Khanna; Ruanne V Barnabas; Steven M Goodreau; Jared M Baeten; Connie Celum; Susan Cassels
Journal:  J Int AIDS Soc       Date:  2016-05-11       Impact factor: 5.396

6.  Estimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling Analysis.

Authors:  Aditya S Khanna; Sarah T Roberts; Susan Cassels; Roger Ying; Grace John-Stewart; Steven M Goodreau; Jared M Baeten; Pamela M Murnane; Connie Celum; Ruanne V Barnabas
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

7.  The increased effectiveness of HIV preventive intervention among men who have sex with men and of follow-up care for people living with HIV after 'task-shifting' to community-based organizations: a 'cash on service delivery' model in China.

Authors:  Hongjing Yan; Min Zhang; Jinkou Zhao; Xiping Huan; Jianping Ding; Susu Wu; Chenchen Wang; Yuanyuan Xu; Li Liu; Fei Xu; Haitao Yang
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.